INmune Bio Inc.
INMBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeINmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. The company carries a $69.7M market cap, placing it firmly in the micro-cap category. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Market Cap
$69.7M
Beta
0.94
P/E (TTM)
—
P/E (Fwd)
-5.12
EPS (TTM)
$-0.62
EPS (Fwd)
$-0.49
ROE
-74.8%
ROA
-39.1%
Cash
$18.4M
Total Debt
$1.4M
Free CF
-$10.0M
52W Change
37.1%
Annual Financials
Cash vs Debt
Where INMB stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, INMB finished 50.64% above its 150-day moving average ($1.56) and 47.80% above its 200-day moving average ($1.59). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INMB overbought or oversold?
At the September 3, 2026 close, INMB's RSI(14) was 64.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $18.4M in cash comfortably exceeding the $1.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$10.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -74.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $374K (2022) to $50K (2025), a 87% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing INMB.